These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36172901)

  • 1. Expanding Access to Naloxone: A Necessary Step to Curb the Opioid Epidemic.
    Houser R
    Disaster Med Public Health Prep; 2022 Sep; 17():e245. PubMed ID: 36172901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study.
    Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC
    Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the impact of naloxone dispensation at public health vending machines in Clark County, Nevada.
    Allen ST; O'Rourke A; Johnson JA; Cheatom C; Zhang Y; Delise B; Watkins K; Reich K; Reich R; Lockett C
    Ann Med; 2022 Dec; 54(1):2692-2700. PubMed ID: 36168975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naloxone's role in the national opioid crisis-past struggles, current efforts, and future opportunities.
    Bennett AS; Elliott L
    Transl Res; 2021 Aug; 234():43-57. PubMed ID: 33684591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Legal requirements and recommendations to prescribe naloxone.
    Haffajee RL; Cherney S; Smart R
    Drug Alcohol Depend; 2020 Apr; 209():107896. PubMed ID: 32058248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A medical student-led model for telephone-based opioid overdose education and naloxone distribution during the COVID-19 pandemic.
    Hughes TM; Kalicki A; Huxley-Reicher Z; Toribio W; Samuels DL; Weiss JJ; Herscher M; Wang L
    Subst Abus; 2022; 43(1):988-992. PubMed ID: 35435812
    [No Abstract]   [Full Text] [Related]  

  • 7. Designing a public access naloxone program for public transportation stations.
    Kohli S; Garg J; Velasquez DE; Weiner SG
    Healthc (Amst); 2023 Jun; 11(2):100694. PubMed ID: 37247465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing and combating the opioid epidemic in the Los Angeles County jail system.
    Tran NT; Muradian IK; Qureshi N; Singh J; Henderson SO
    J Subst Use Addict Treat; 2023 Apr; 147():208984. PubMed ID: 36841073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicaid prescription limits and their implications for naloxone accessibility.
    Roberts AW; Look KA; Trull G; Carpenter DM
    Drug Alcohol Depend; 2021 Jan; 218():108355. PubMed ID: 33309522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Opioid Crisis, Centers for Disease Control Opioid Guideline, and Naloxone Coprescription for Patients at Risk for Opioid Overdose.
    Benzon HT; Sun EC; Chou R
    Anesth Analg; 2022 Jul; 135(1):21-25. PubMed ID: 35709441
    [No Abstract]   [Full Text] [Related]  

  • 12. Simulating the Simultaneous Impact of Medication for Opioid Use Disorder and Naloxone on Opioid Overdose Death in Eight New York Counties.
    Cerdá M; Hamilton AD; Hyder A; Rutherford C; Bobashev G; Epstein JM; Hatna E; Krawczyk N; El-Bassel N; Feaster DJ; Keyes KM
    Epidemiology; 2024 May; 35(3):418-429. PubMed ID: 38372618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "A Blessing and a Curse:" Opioid Users' Perspectives on Naloxone and the Epidemic of Opioid Overdose.
    Kline A; Mattern D; Cooperman N; Dooley-Budsock P; Williams JM; Borys S
    Subst Use Misuse; 2020; 55(8):1280-1287. PubMed ID: 32182153
    [No Abstract]   [Full Text] [Related]  

  • 14. Opioid overdose prevention education in Texas during the COVID-19 pandemic.
    Mathias CW; Cavazos DM; McGlothen-Bell K; Crawford AD; Flowers-Joseph B; Wang Z; Cleveland LM
    Harm Reduct J; 2023 Mar; 20(1):37. PubMed ID: 36964600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes to opioid overdose deaths and community naloxone access among Black, Hispanic and White people from 2016 to 2021 with the onset of the COVID-19 pandemic: An interrupted time-series analysis in Massachusetts, USA.
    Zang X; Walley AY; Chatterjee A; Kimmel SD; Morgan JR; Murphy SM; Linas BP; Nolen S; Reilly B; Urquhart C; Schackman BR; Marshall BDL
    Addiction; 2023 Dec; 118(12):2413-2423. PubMed ID: 37640687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statewide efforts to address the opioid epidemic: Results from a national survey of single state agencies.
    Estrada MAG; Abraham AJ; Andrews CM; Grogan CM
    J Subst Use Addict Treat; 2024 May; 160():209309. PubMed ID: 38336265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone.
    Kline A; Williams JM; Steinberg ML; Mattern D; Chesin M; Borys S; Chaguturu V
    J Subst Use Addict Treat; 2023 Jun; 149():209028. PubMed ID: 37003539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naloxone administration among opioid-involved overdose deaths in 38 United States jurisdictions in the State Unintentional Drug Overdose Reporting System, 2019.
    Quinn K; Kumar S; Hunter CT; O'Donnell J; Davis NL
    Drug Alcohol Depend; 2022 Jun; 235():109467. PubMed ID: 35461083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths.
    ; Samet JH; El-Bassel N; Winhusen TJ; Jackson RD; Oga EA; Chandler RK; Villani J; Freisthler B; Adams J; Aldridge A; Angerame A; Babineau DC; Bagley SM; Baker TJ; Balvanz P; Barbosa C; Barocas J; Battaglia TA; Beard DD; Beers D; Blevins D; Bove N; Bridden C; Brown JL; Bush HM; Bush JL; Caldwell R; Calver K; Calvert D; Campbell ANC; Carpenter J; Caspar R; Chassler D; Chaya J; Cheng DM; Cunningham CO; Dasgupta A; David JL; Davis A; Dean T; Drainoni ML; Eggleston B; Fanucchi LC; Feaster DJ; Fernandez S; Figueroa W; Freedman DA; Freeman PR; Freiermuth CE; Friedlander E; Gelberg KH; Gibson EB; Gilbert L; Glasgow L; Goddard-Eckrich DA; Gomori S; Gruss DE; Gulley J; Gutnick D; Hall ME; Harger Dykes N; Hargrove SL; Harlow K; Harris A; Harris D; Helme DW; Holloway J; Hotchkiss J; Huang T; Huerta TR; Hunt T; Hyder A; Ingram VL; Ingram T; Kauffman E; Kimball JL; Kinnard EN; Knott C; Knudsen HK; Konstan MW; Kosakowski S; Larochelle MR; Leaver HM; LeBaron PA; Lefebvre RC; Levin FR; Lewis N; Lewis N; Lofwall MR; Lounsbury DW; Luster JE; Lyons MS; Mack A; Marks KR; Marquesano S; Mauk R; McAlearney AS; McConnell K; McGladrey ML; McMullan J; Miles J; Munoz Lopez R; Nelson A; Neufeld JL; Newman L; Nguyen TQ; Nunes EV; Oller DA; Oser CB; Oyler DR; Pagnano S; Parran TV; Powell J; Powers K; Ralston W; Ramsey K; Rapkin BD; Reynolds JG; Roberts MF; Robertson W; Rock P; Rodgers E; Rodriguez S; Rudorf M; Ryan S; Salsberry P; Salvage M; Sabounchi N; Saucier M; Savitzky C; Schackman B; Schady E; Seiber EE; Shadwick A; Shoben A; Slater MD; Slavova S; Speer D; Sprunger J; Starbird LE; Staton M; Stein MD; Stevens-Watkins DJ; Stopka TJ; Sullivan A; Surratt HL; Sword Cruz R; Talbert JC; Taylor JL; Thompson KL; Vandergrift N; Vickers-Smith RA; Vietze DJ; Walker DM; Walley AY; Walters ST; Weiss R; Westgate PM; Wu E; Young AM; Zarkin GA; Walsh SL
    N Engl J Med; 2024 Sep; 391(11):989-1001. PubMed ID: 38884347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of untargeted naloxone distribution on opioid overdose outcomes.
    Dowd WN
    Health Econ; 2023 Dec; 32(12):2801-2818. PubMed ID: 37670413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.